<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <title>MyProject</title>
    <link rel="stylesheet" href="bundle.min.css">
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.4.1/jquery.min.js"></script>
</head>
<body>
<section class="main">
<header>
    <section>
        <div class="mainLogo">
            <div class="logo">
                  <img src="images/BRIV_LOGO_mobile.jpg" alt="Logo image"
                  srcset="images/BRIV_LOGO_mobile.jpg 400w, images/BRIV_Logo_391x114_-_IN_BUILD_KIT.png 750w"
                  sizes="(min-width: 1024px) 35vw,
                  (min-width: 640px) and (max-width: 1023px) 50vw,
                  (max-width: 639px) 100vw">  
            </div>
            <div class="text">
               <p> Important Safety Information | Prescribing Information | For Patient</p>
               <img src="images/ucbCARES®_1-844-599-CARE_(2273).png" alt="ucb">
            </div>
        </div>
    </section>
    <div>
      <div class="bgImg">  
        <img src="images/BACK_ANGLE.png" width="100%">
      </div>
        <div> 
           
            <nav class="navMenu">     
                <div class="hamburger-container">
                    <ul class="hamburger">
                      <li></li>
                      <li></li>
                      <li></li>
                    </ul>
                </div>
             
                <a href="#" class="list">OVERVIEW</a>
                <a href="#" class="list">MOA</a>
                <a href="#" class="list">PK PROFILE</a>
                <a href="#" class="list">ADMINISTRATION</a>
                <a href="#" class="list">ADULT EFFICACY</a>
                <a href="#" class="list">SAFETY AND TOLERABILITY</a>
                <a href="#" class="list">HOSPITAL DISCHARGE</a>
        
            </nav>
        </div>
        <div>

        <div class="headerText first">BRIVIACT® (BRIVARACETAM) CV INJECTION FOR ADULT <br>
            PARTIAL-ONSET SEIZURE PATIENTS IN THE HOSPITAL</div>
          
            <hr>
        <div class="headerText second">BECAUSE IN NEUROCRITICAL CARE, THERE IS LIMITED TIME <br>
            FOR COMPLICATED ADMINISTRATION</div>
        </div>
    
        <div class="triangle"> 
            <img src="images/H.1_Left_Chevron_Graphic_174x445_-_IN_BUILD_KIT.png" alt="triangle"
            srcset="images/H.1_Left_Chevron_Graphic_174x445_-_IN_BUILD_KIT.png 1110w, images/H.1_Left_Chevron_mobile.png 680w"
            sizes="(min-width: 1024px) 100vw,
            (min-width: 640px) and (max-width: 1023px) 100vw,
            (max-width: 639px) 100vw">  
        </div>
       
    </div>
   
</header>
<main>
    <section class="mainSection">
       
        <img src="images/TAN_SHAPE.png" alt="bgImage" width="100%"> 

        <article class="firstArticle">
            <h2>Adult efficacy was established in pivotal trials</h2>
            <p class="subtitle">Pivotal trial program design and results<sup>1</sup></p>
            <div class="mainSectionBlock">
                <div class="trialDesign">
                    <ul>Trial design 
                        <li>Effectiveness was established in 3 fixed-dose, randomized, double-blind, placebo-controlled, multicenter studies, which included 1550 adult patients<sup>1</sup> 
                        <li>Enrolled adult patients had partial-onset seizures that were not adequately controlled by 1 to 2 concomitant antiepileptic drugs (AEDs)<sup>1</sup>
                        <li>Adult patients taking concomitant levetiracetam were excluded from Study 3<sup>1</sup>
                    </ul>            
                </div>
                <div class="trialResult">
                    <ul>Trial results 
                        <li>25.2% and 25.7% reduction over placebo with BRIVIACT 100 mg/day (n=252) and 200 mg/day (n=249) respectively in partial-onset seizure frequency adjusted to 28 days during the treatment period in Study 3, when added to current therapy<sup>1</sup></li> 
                        <li>≥50% response achieved by 30.0%, 38.1%, and 37.8% of patients with BRIVIACT 50 mg/day, 100 mg/day, and 200 mg/day vs. 20.2% with placebo in pooled results from all three studies<sup>8</sup></li>
                   </ul>
                 </div>
                <div class="briviant">
                    <p class="subtitle">BRIVIACT was efficacious in patients who had prior levetiracetam EXPOSURE</p>
                        <ul> In Study 3, approximately 54% of adult patients had prior exposure to levetiracetam and were evaluated in a pre-specified analysis. Adult patients taking concomitant levetiracetam were excluded from the study.<sup>1</sup> 
                            <li>18.2% and 21.3% reduction over placebo with BRIVIACT 100 mg/day and 200 mg/day, respectively, in partial-onset seizure frequency adjusted to 28 days during the treatment period in Study 3 in patients with prior levetiracetam exposure<sup>8</sup></li>
                                <br>     
                                <figure>
                                    <figcaption>Reasons for discontinuing levetiracetam prior to inclusion in Study 3<sup>8</sup>:</figcaption>
                                         <img src="images/Vector_Smart_Object.png" alt="percents">
                                 </figure>  
                            <li>BRIVIACT studies showed no additional benefit when co-administered with levetiracetam<sup>1</sup></li>
                       </ul>
                </div>
            </div>
        </article>
    </section>
</main>

<footer>
    <div class="footerBlock">
        <h4>Contact information</h4>
        <div class="footerBlock1">If you have any questions or want more information, please contact ucbCARES® at 1-844-599-CARE (2273) or ucbCARES@UCB.com. We're here to help.</div>
        <div class="footerBlock2">Important Safety Information  |  Prescribing Information  |  Privacy Policy  |  Terms of Use  |  Contact Us</div>
        <div class="footerBlock3">BRIVIACT® and ucbCARES® are registered trademarks of the UCB Group of Companies.
            All other trademarks are the property of their respective holders.
            ©2020 UCB, Inc., Smyrna, GA 30080. All rights reserved.
            US-P-BR-EPOS-2000022 </div>
        <div class="footerBlock4">
            <img src="images/ucb_1c_wht_w_tag.png" alt="footerLogo">
           <p> UCB Inc., 1950 Lake Park Driv <br> Smyrna, GA 30080</p>
        </div>
    </div>
</footer>
</section>
<script>
    $(document).ready(function() {
  //toggle menu
  $(".hamburger-container").click(function() {
   $(".list").slideToggle();
  });

  //icon animation
  var topBar = $(".hamburger li:nth-child(1)"),
    middleBar = $(".hamburger li:nth-child(2)"),
    bottomBar = $(".hamburger li:nth-child(3)");

  $(".hamburger-container").on("click", function() {
    if (middleBar.hasClass("rot-45deg")) {
      topBar.removeClass("rot45deg");
      middleBar.removeClass("rot-45deg");
      bottomBar.removeClass("hidden");
    } else {
      bottomBar.addClass("hidden");
      topBar.addClass("rot45deg");
      middleBar.addClass("rot-45deg");
    }
  });
});

</script>
</body>
</html>